EuroBiotech: More Articles of Note

Newspapers
(Image: NS Newsflash/CC BY 2.0)

> CureVac unveiled leadership changes. Ingmar Hoerr is set to transition to the chairman role, leaving the CEO seat free for Daniel Menichella. Release

> InflaRx netted $57.1 million in a stock offering. The financing sets InflaRx up to run midphase trials of antihuman C5a monoclonal antibody IFX-1. Statement 

> Memo Therapeutics raised CHF 5 million ($5 million) to advance its antibody candidates. Release

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Motif Bio hired Stephanie Noviello, M.D., to support its filing for approval of iclaprim in Europe. Noviello joins the antibiotic drug developer from Bristol-Myers Squibb. Statement (PDF) 

> French authorities cleared Advicenne to start a phase 2/3 trial of its lead candidate in cystinuria, a rare inherited disease that causes recurrent kidney stone formation. Release  

> Lundbeck gave up trying to fix a manufacturing problem that has stymied commercialization of Carnexiv. The FDA approved the seizure drug in 2016 but Lundbeck subsequently ran into a problem it has been unable to solve. Lundbeck is now looking to divest the asset. Statement (PDF)

Suggested Articles

Sumitovant CEO Myrtle Potter discusses the $3 billion Roivant-Sumitomo deal, her role at Sumitovant and what's up in 2020.

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection.

In this week's EuroBiotech Report, Roche's risdiplam clears another phase 3 SMA trial, Merck KGaA spinout raises cash and Korean VCs back PDC*line.